{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:36Z","timestamp":1792790436996,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to assess the efficacy and safety of combining transarterial chemoembolization and hepatic arterial infusion chemotherapy (TACE-HAIC) with targeted immunotherapy in patients with primary hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus (PVTT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed clinical data from 114 patients with HCC and PVTT treated with either a quadruple-therapy group (TACE-HAIC plus targeted immunotherapy) or a triple-therapy group (TACE plus targeted immunotherapy) at the Affiliated Hospital of Xuzhou Medical University from January 2019 to September 2023. Propensity score matching was applied to these 114 patients. We compared outcomes such as overall survival (OS), progression-free survival (PFS), intrahepatic progression-free survival (IHPFS), PVTT progression-free survival (TTPFS), objective response rate (ORR), disease control rate (DCR), and the incidence of adverse events between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The quadruple-therapy group exhibited a markedly superior ORR of portal vein tumor thrombus relative to the triple-therapy group (P&amp;lt;0.05). However, no significant differences were found between the groups in OS, PFS, IHPFS, or TTPFS (P &amp;gt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The combination of TACE-HAIC with targeted immunotherapy (the quadruple-therapy group) is an effective treatment strategy for PVTT, significantly inducing regression of intraportal tumor thrombi and achieving a higher objective response rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1811934","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:25:37Z","timestamp":1781497537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus"],"prefix":"10.3389","volume":"16","author":[{"given":"Shaoqin","family":"Yang","sequence":"first","affiliation":[{"name":"Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangshuang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Gu","sequence":"additional","affiliation":[{"name":"Interventional Radiology Department, The Affiliated Hospital of Xuzhou Medical University","place":["Xuzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","first-page":"17","article-title":"Guidelines for the diagnosis and treatment of primary liver cancer (2024)","volume":"10","year":"2024","journal-title":"J Multidiscip Cancer Manag (Electr Ed)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet (Lond Engl)"},{"key":"B3","article-title":"Further discussion on the precision TACE therapy","volume":"30","author":"Wen","year":"2021","journal-title":"Interv Radiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","article-title":"Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update","volume":"10","author":"Kudo","year":"2021","journal-title":"Liv Cancer"},{"key":"B5","first-page":"JCO2100608","article-title":"Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial","volume":"40","author":"Li","year":"2021","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"JCO2101963","DOI":"10.1200\/jco.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(19)30178-5","article-title":"Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west","volume":"4","author":"Lu","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-023-01976-x","article-title":"Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis","volume":"58","author":"Fu","year":"2023","journal-title":"J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000503685","article-title":"Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018)","volume":"35","author":"Chen","year":"2019","journal-title":"J Clin Hepatol"},{"key":"B11","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatol (Balt Md)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"8165","DOI":"10.3390\/ijms21218165","article-title":"Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma","volume":"21","author":"Chang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.s455953","article-title":"High-risk hepatocellular carcinoma: hepatic arterial infusion chemotherapy versus transarterial chemoembolization","volume":"11","author":"Zhang","year":"2024","journal-title":"J Hepatocellular Carcinoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12885-024-12233-6","article-title":"HAIC combined with lenvatinib plus PD-1 versus lenvatinib plus PD-1 in patients with high-risk advanced HCC: a real-world study","volume":"24","author":"Chang","year":"2024","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12957-021-02401-4","article-title":"Combination of transcatheter arterial chemoembolization and portal vein embolization for patients with hepatocellular carcinoma: a review","volume":"19","author":"Shao","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000566","article-title":"The efficacy and safety of TACE or HAIC combined with ICIs and angiogenesis inhibitors in unresectable hepatocellular carcinoma","volume":"48","author":"Wu","year":"2025","journal-title":"J Immunother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.37766\/inplasy2024.8.0012","article-title":"Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"32","author":"Jiang","year":"2024","journal-title":"Acad Radiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15010","article-title":"Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis","volume":"35","author":"Liu","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"B20","first-page":"494","article-title":"Analysis of downstaging and conversion therapy in 64 cases of advanced hepatocellular carcinoma","volume":"35","author":"Bingfu","year":"2023","journal-title":"J Hepatopancreatob Surg"},{"key":"B21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12072-025-10884-6","article-title":"Hepatic arterial infusion chemotherapy combined with lenvatinib and programmed death receptor-1 inhibitors for hepatocellular carcinoma with Vp4 portal vein tumor thrombus: a multicenter, propensity score matching comparative study","volume":"20","author":"Wu","year":"2025","journal-title":"Hepatol Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-024-10762-7","article-title":"HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion","volume":"19","author":"Tang","year":"2025","journal-title":"Hepatol Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-93","article-title":"Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience","volume":"13","author":"Zhao","year":"2024","journal-title":"Trans Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:25:42Z","timestamp":1781497542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1811934"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1811934","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1811934"}}